Author:
Zagnoli F.,Vérin M.,Tirel A.,Tir M.,Ory-Magne F.,Marques A.,Maltête D.,Frismand S.,Fluchère F.,Drapier S.,Defebvre L.,Decombe R.,Bereau M.,Bannier S.
Reference21 articles.
1. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial;Katzenschlager;Lancet Neurol,2018
2. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study;Katzenschlager;Parkinsonism Relat Disord,2021
3. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study;Cock;Lancet Neurol,2022
4. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease;Todorova;Parkinsonism Relat Disord,2013
5. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients;Borgemeester;Parkinsonism Relat Disord,2016